DSRV Articles
Warning-letter analysis, 483 trend reports, and regulatory intelligence for pharma quality teams. Every piece is cited, verified, and written by our Intelligence team.
3 of 48 articles · FDA Response·Browse by regulation →
August 2026
FDA’s 2025–2026 Warning-Letter Pattern: Water Systems Are Still Breaking Quality Systems, Not Just Utilities
If your water system is unstable, FDA is not just looking at maintenance. Recent warning letters show water-related failures treated as systemic failures in investigations, CAPA, product risk, and quality oversight.
June 2026
How to Respond to an FDA 483 Without Overcommitting
An FDA Form 483 lists inspectional observations, not final agency conclusions. The strongest responses are specific, evidence-led, and scoped — committing to what you can verifiably deliver rather than promising the world.
June 2026
CAPA Response Strategy: What FDA Expects to See
A strong CAPA is more than a corrective fix — FDA expects a defensible root cause, a systemic corrective and preventive action, and a real effectiveness check. Here is how to structure one that holds up.
